LAUSR

Purpose of ReviewAntiplatelet therapy for patients undergoing percutaneous coronary intervention has rapidly evolved over the last 10 years, often outpacing clinical guidelines. This review appraises recent clinical trials within the context of landmark trials in interventional cardiology, and offers a framework for the integration of recent trials into clinical practice.Recent FindingsThis review interprets recent evidence regarding the following: (1) aspirin and the most effective dose; (2) the role of the newer, more potent P2Y12 inhibitors prasugrel, ticagrelor, and cangrelor; (3) an appraisal of the evolving paradigm for duration of dual antiplatelet therapy; and (4) perspective on the role of glycoprotein IIb/IIIa inhibitors in the era of routine and potent P2Y12 inhibition.SummaryThe newer and more potent P2Y12 inhibitors, as well as a more nuanced understanding of mainstays of treatment like aspirin, offer the promise of maximizing ischemic benefit and minimizing bleeding in patients undergoing percutaneous coronary intervention.